<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="561">
  <stage>Registered</stage>
  <submitdate>14/04/2005</submitdate>
  <approvaldate>14/04/2005</approvaldate>
  <nctid>NCT00108134</nctid>
  <trial_identification>
    <studytitle>Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma</studytitle>
    <scientifictitle>A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 &amp; 2 or Day 1 &amp; 8 Applications to Superficial Basal Cell Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2005/154</secondaryid>
    <secondaryid>PEP005-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Basal Cell Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PEP005

Treatment: drugs: PEP005


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female patients at least 18 years of age

          -  One sBCC on the arm, shoulder, chest, face, neck, abdomen, leg, back or scalp suitable
             for surgical excision

          -  Histological confirmation of sBCC based on the central dermatopathologist's evaluation
             of the punch biopsy

          -  Longest pre- and post-biopsy diameter of the sBCC lesion between 4 mm and 15 mm

          -  Maximum thickness of 4 mm of the sBCC lesion

          -  Laboratory values within the reference ranges as defined by the central laboratory or
             "out of range" test results that are clinically acceptable to the Investigator

          -  Ability to follow study instructions and likely to complete all study requirements

          -  Written informed consent

          -  Male patients with a female partner of childbearing potential must use an approved
             form of contraception during the study and for 4 weeks after the last visit

          -  Agreement from the patient to allow photographs of all selected lesions (including the
             face) to be taken and used as part of the study data package</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Location of the outside margin of the anticipated treatment area of the sBCC selected
             for treatment:

               1. within 10 cm of a malignant lesion that will require treatment during the study

               2. within 5 cm of an incompletely healed wound

               3. within 2 cm of a pre-malignant lesion (e.g. actinic keratosis lesion)

               4. within 2 cm of the open eyelid margins

               5. within 1 cm of a scar or an area previously treated with surgical excision

               6. on the lips

               7. on the breast

               8. on the hand or foot

               9. in a skin crease

          -  sBCC lesion selected for treatment requiring Mohs micrographic surgery

          -  Presence of known or suspected metastatic disease

          -  Histological evidence of actinic keratoses or nBCC in the screening visit biopsy
             sample

          -  Histological evidence of BCC with micro-nodular features or squamous metaplasia,
             sclerosing BCC (i.e. desmoplastic or morphoeic), or BCC with perineural involvement in
             the screening visit biopsy sample

          -  History of recurrence of the sBCC lesion

          -  History or evidence of skin diseases which would interfere with evaluation of the
             treatment area (e.g. eczema, unstable psoriasis, xeroderma pigmentosa)

          -  Known sensitivity to any of the ingredients in the study medication

          -  A cosmetic or therapeutic procedure (e.g. use of liquid nitrogen, surgical excision,
             curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing)
             within 10 cm of the selected sBCC lesion during the 3 months prior to study entry or
             anticipated treatment within 10 cm of the selected lesion during the study

          -  Treatment with 5-fluorouracil, imiquimod, diclofenac or photodynamic therapy:

               1. of lesions located within 10 cm of the selected sBCC lesion during the 3 months
                  prior to study entry or

               2. anywhere during the 4 weeks prior to study entry or anticipated treatment during
                  the study

          -  Use of acid-containing products (e.g. salicylic acids or fruit acids, such as alpha
             and beta hydroxy acids and glycolic acids), topical retinoids or light chemical peels
             within 10 cm of the selected sBCC lesion during the 3 months prior to study entry or
             anticipated treatment in this same area during the study

          -  Treatment with immuno-modulators (e.g. cyclosporine, prednisone, methotrexate,
             infliximab or other biological agents), cytotoxic drugs (e.g. vinblastine,
             cyclophosphamide, azathioprine, chlorambucil, methotrexate), or interferon/interferon
             inducers during the 4 weeks prior to study entry or anticipated treatment during the
             study

          -  Treatment with psoralen plus UVA or use of UVB therapy during the 6 months prior to
             study entry or anticipated treatment during the study

          -  Use of systemic retinoids (e.g. isotretinoin, acitretin) during the 6 months prior to
             study entry or anticipated treatment during the study

          -  Anticipated excessive or prolonged exposure to ultraviolet light (e.g. sunlight,
             tanning beds) or use of topical salves, creams or ointments to the selected lesion
             during the study

          -  Anticipated need for hospitalization or non-dermatological surgery during the study

          -  Concurrent disease that suppresses the immune system (e.g. HIV) or uncontrolled
             systemic disease (e.g. uncontrolled hypertension, poorly controlled diabetes)

          -  Current evidence of chronic alcohol or drug abuse

          -  Current enrolment in an investigational drug or device study or participation in such
             a study within 30 days of entry into this study

          -  Diagnosis of xeroderma pigmentosa or Gorlin Syndrome (i.e. Basal Cell Nevus Syndrome)

          -  A condition or situation which in the Investigator's opinion may put the patient at
             significant risk, may confound the study results, or may interfere significantly with
             the patient's participation in the study

          -  Females of child bearing potential (a female is considered of childbearing potential
             unless she is postmenopausal, i.e., no menses for at least 12 consecutive months, or
             is without a uterus)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Southderm Pty Ltd - Sydney</hospital>
    <hospital>St George Dermatology &amp; Skin Cancer Centre - Sydney</hospital>
    <hospital>Siller Medical - Brisbane</hospital>
    <hospital>Belmont Specialist Centre - Brisbane</hospital>
    <hospital>The Skin Centre - Gold Coast</hospital>
    <hospital>Skin and Cancer Foundation - Melbourne</hospital>
    <hospital>Freemantle Dermatology - Freemantle</hospital>
    <hospital>Private Dermaology Clinic - Fremantle</hospital>
    <hospital>St John of God Dermatology - Subiaco</hospital>
    <postcode>2010 - Sydney</postcode>
    <postcode>2217 - Sydney</postcode>
    <postcode>4000 - Brisbane</postcode>
    <postcode>4152 - Brisbane</postcode>
    <postcode>4217 - Gold Coast</postcode>
    <postcode>3053 - Melbourne</postcode>
    <postcode>6160 - Freemantle</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>6008 - Subiaco</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Peplin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether topical application of PEP005 is safe for
      the treatment of superficial basal cell carcinoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00108134</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Greg Siller</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>